English
简体中文
Total: £ 56.28
Published Date: 2024-04-08 | Pages: 88 | Tables: 200 | Pharma & Healthcare
The global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Pegylated Recombinant Human Granulocyte Colony Stimulating Factor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Pegylated Recombinant Human Granulocyte Colony Stimulating Factor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor include Amgen, Apotex, Coherus BioSciences, Fresenius Kabi Deutschland, Juta Pharma, Mundipharma, Novartis, Pfizer and Viatris, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Pegylated Recombinant Human Granulocyte Colony Stimulating Factor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pegylated Recombinant Human Granulocyte Colony Stimulating Factor.
Report Scope
The Pegylated Recombinant Human Granulocyte Colony Stimulating Factor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pegylated Recombinant Human Granulocyte Colony Stimulating Factor manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen
Apotex
Coherus BioSciences
Fresenius Kabi Deutschland
Juta Pharma
Mundipharma
Novartis
Pfizer
Viatris
Hengrui Pharmaceuticals
Lunan Pharmaceutical
Qilu Pharmaceutical Co., Ltd.
CSPC Pharmaceutical Group Limited
Segment by Type
Vials
Prefilled
Segment by Application
Myelosuppressive Chemotherapy for Nonmyeloid Neoplasms
Chemotherapy for Hematological Malignancies Myelosuppression
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Overview
1.1 Product Overview and Scope of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor
1.2 Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Segment by Type
1.2.1 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Value Comparison by Type (2024-2030)
1.2.2 Vials
1.2.3 Prefilled
1.3 Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Segment by Application
1.3.1 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Value by Application: (2024-2030)
1.3.2 Myelosuppressive Chemotherapy for Nonmyeloid Neoplasms
1.3.3 Chemotherapy for Hematological Malignancies Myelosuppression
1.4 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Size Estimates and Forecasts
1.4.1 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue 2019-2030
1.4.2 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales 2019-2030
1.4.3 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Competition by Manufacturers
2.1 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales Market Share by Manufacturers (2019-2024)
2.2 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Average Price by Manufacturers (2019-2024)
2.4 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor, Product Type & Application
2.7 Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Competitive Situation and Trends
2.7.1 Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Players Market Share by Revenue
2.7.3 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Retrospective Market Scenario by Region
3.1 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales by Region: 2019-2030
3.2.1 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales by Region: 2019-2024
3.2.2 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales by Region: 2025-2030
3.3 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Region: 2019-2030
3.3.1 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Region: 2019-2024
3.3.2 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Region: 2025-2030
3.4 North America Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Facts & Figures by Country
3.4.1 North America Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales by Country (2019-2030)
3.4.3 North America Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Facts & Figures by Country
3.5.1 Europe Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales by Country (2019-2030)
3.5.3 Europe Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Facts & Figures by Country
3.6.1 Asia Pacific Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales by Country (2019-2030)
3.6.3 Asia Pacific Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Facts & Figures by Country
3.7.1 Latin America Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales by Country (2019-2030)
3.7.3 Latin America Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Facts & Figures by Country
3.8.1 Middle East and Africa Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales by Country (2019-2030)
3.8.3 Middle East and Africa Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales by Type (2019-2030)
4.1.1 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales by Type (2019-2024)
4.1.2 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales by Type (2025-2030)
4.1.3 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales Market Share by Type (2019-2030)
4.2 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Type (2019-2030)
4.2.1 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Type (2019-2024)
4.2.2 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Type (2025-2030)
4.2.3 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Market Share by Type (2019-2030)
4.3 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Price by Type (2019-2030)
5 Segment by Application
5.1 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales by Application (2019-2030)
5.1.1 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales by Application (2019-2024)
5.1.2 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales by Application (2025-2030)
5.1.3 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales Market Share by Application (2019-2030)
5.2 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Application (2019-2030)
5.2.1 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Application (2019-2024)
5.2.2 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Application (2025-2030)
5.2.3 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Market Share by Application (2019-2030)
5.3 Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Corporation Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Amgen Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 Apotex
6.2.1 Apotex Corporation Information
6.2.2 Apotex Description and Business Overview
6.2.3 Apotex Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Apotex Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Product Portfolio
6.2.5 Apotex Recent Developments/Updates
6.3 Coherus BioSciences
6.3.1 Coherus BioSciences Corporation Information
6.3.2 Coherus BioSciences Description and Business Overview
6.3.3 Coherus BioSciences Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Coherus BioSciences Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Product Portfolio
6.3.5 Coherus BioSciences Recent Developments/Updates
6.4 Fresenius Kabi Deutschland
6.4.1 Fresenius Kabi Deutschland Corporation Information
6.4.2 Fresenius Kabi Deutschland Description and Business Overview
6.4.3 Fresenius Kabi Deutschland Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Fresenius Kabi Deutschland Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Product Portfolio
6.4.5 Fresenius Kabi Deutschland Recent Developments/Updates
6.5 Juta Pharma
6.5.1 Juta Pharma Corporation Information
6.5.2 Juta Pharma Description and Business Overview
6.5.3 Juta Pharma Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Juta Pharma Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Product Portfolio
6.5.5 Juta Pharma Recent Developments/Updates
6.6 Mundipharma
6.6.1 Mundipharma Corporation Information
6.6.2 Mundipharma Description and Business Overview
6.6.3 Mundipharma Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Mundipharma Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Product Portfolio
6.6.5 Mundipharma Recent Developments/Updates
6.7 Novartis
6.6.1 Novartis Corporation Information
6.6.2 Novartis Description and Business Overview
6.6.3 Novartis Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Novartis Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Product Portfolio
6.7.5 Novartis Recent Developments/Updates
6.8 Pfizer
6.8.1 Pfizer Corporation Information
6.8.2 Pfizer Description and Business Overview
6.8.3 Pfizer Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Pfizer Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Product Portfolio
6.8.5 Pfizer Recent Developments/Updates
6.9 Viatris
6.9.1 Viatris Corporation Information
6.9.2 Viatris Description and Business Overview
6.9.3 Viatris Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Viatris Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Product Portfolio
6.9.5 Viatris Recent Developments/Updates
6.10 Hengrui Pharmaceuticals
6.10.1 Hengrui Pharmaceuticals Corporation Information
6.10.2 Hengrui Pharmaceuticals Description and Business Overview
6.10.3 Hengrui Pharmaceuticals Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Hengrui Pharmaceuticals Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Product Portfolio
6.10.5 Hengrui Pharmaceuticals Recent Developments/Updates
6.11 Lunan Pharmaceutical
6.11.1 Lunan Pharmaceutical Corporation Information
6.11.2 Lunan Pharmaceutical Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Description and Business Overview
6.11.3 Lunan Pharmaceutical Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Lunan Pharmaceutical Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Product Portfolio
6.11.5 Lunan Pharmaceutical Recent Developments/Updates
6.12 Qilu Pharmaceutical Co., Ltd.
6.12.1 Qilu Pharmaceutical Co., Ltd. Corporation Information
6.12.2 Qilu Pharmaceutical Co., Ltd. Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Description and Business Overview
6.12.3 Qilu Pharmaceutical Co., Ltd. Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Qilu Pharmaceutical Co., Ltd. Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Product Portfolio
6.12.5 Qilu Pharmaceutical Co., Ltd. Recent Developments/Updates
6.13 CSPC Pharmaceutical Group Limited
6.13.1 CSPC Pharmaceutical Group Limited Corporation Information
6.13.2 CSPC Pharmaceutical Group Limited Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Description and Business Overview
6.13.3 CSPC Pharmaceutical Group Limited Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales, Revenue and Gross Margin (2019-2024)
6.13.4 CSPC Pharmaceutical Group Limited Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Product Portfolio
6.13.5 CSPC Pharmaceutical Group Limited Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Industry Chain Analysis
7.2 Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Production Mode & Process
7.4 Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales and Marketing
7.4.1 Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales Channels
7.4.2 Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Distributors
7.5 Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Customers
8 Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Dynamics
8.1 Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Industry Trends
8.2 Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Drivers
8.3 Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Challenges
8.4 Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Competitive Situation by Manufacturers in 2023
Table 4. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor, Product Type & Application
Table 12. Global Key Manufacturers of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pegylated Recombinant Human Granulocyte Colony Stimulating Factor as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales by Region (2019-2024) & (K Units)
Table 18. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales Market Share by Region (2019-2024)
Table 19. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales by Region (2025-2030) & (K Units)
Table 20. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales Market Share by Region (2025-2030)
Table 21. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Market Share by Region (2019-2024)
Table 23. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Market Share by Region (2025-2030)
Table 25. North America Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales by Country (2019-2024) & (K Units)
Table 27. North America Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales by Country (2025-2030) & (K Units)
Table 28. North America Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales by Country (2019-2024) & (K Units)
Table 32. Europe Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales by Country (2025-2030) & (K Units)
Table 33. Europe Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales (K Units) by Type (2019-2024)
Table 51. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales (K Units) by Type (2025-2030)
Table 52. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales Market Share by Type (2019-2024)
Table 53. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales Market Share by Type (2025-2030)
Table 54. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Market Share by Type (2019-2024)
Table 57. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Market Share by Type (2025-2030)
Table 58. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Price (US$/Unit) by Type (2019-2024)
Table 59. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Price (US$/Unit) by Type (2025-2030)
Table 60. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales (K Units) by Application (2019-2024)
Table 61. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales (K Units) by Application (2025-2030)
Table 62. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales Market Share by Application (2019-2024)
Table 63. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales Market Share by Application (2025-2030)
Table 64. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Market Share by Application (2019-2024)
Table 67. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Market Share by Application (2025-2030)
Table 68. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Price (US$/Unit) by Application (2019-2024)
Table 69. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Price (US$/Unit) by Application (2025-2030)
Table 70. Amgen Corporation Information
Table 71. Amgen Description and Business Overview
Table 72. Amgen Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Amgen Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Product
Table 74. Amgen Recent Developments/Updates
Table 75. Apotex Corporation Information
Table 76. Apotex Description and Business Overview
Table 77. Apotex Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Apotex Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Product
Table 79. Apotex Recent Developments/Updates
Table 80. Coherus BioSciences Corporation Information
Table 81. Coherus BioSciences Description and Business Overview
Table 82. Coherus BioSciences Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Coherus BioSciences Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Product
Table 84. Coherus BioSciences Recent Developments/Updates
Table 85. Fresenius Kabi Deutschland Corporation Information
Table 86. Fresenius Kabi Deutschland Description and Business Overview
Table 87. Fresenius Kabi Deutschland Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Fresenius Kabi Deutschland Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Product
Table 89. Fresenius Kabi Deutschland Recent Developments/Updates
Table 90. Juta Pharma Corporation Information
Table 91. Juta Pharma Description and Business Overview
Table 92. Juta Pharma Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Juta Pharma Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Product
Table 94. Juta Pharma Recent Developments/Updates
Table 95. Mundipharma Corporation Information
Table 96. Mundipharma Description and Business Overview
Table 97. Mundipharma Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Mundipharma Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Product
Table 99. Mundipharma Recent Developments/Updates
Table 100. Novartis Corporation Information
Table 101. Novartis Description and Business Overview
Table 102. Novartis Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Novartis Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Product
Table 104. Novartis Recent Developments/Updates
Table 105. Pfizer Corporation Information
Table 106. Pfizer Description and Business Overview
Table 107. Pfizer Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Pfizer Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Product
Table 109. Pfizer Recent Developments/Updates
Table 110. Viatris Corporation Information
Table 111. Viatris Description and Business Overview
Table 112. Viatris Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Viatris Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Product
Table 114. Viatris Recent Developments/Updates
Table 115. Hengrui Pharmaceuticals Corporation Information
Table 116. Hengrui Pharmaceuticals Description and Business Overview
Table 117. Hengrui Pharmaceuticals Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Hengrui Pharmaceuticals Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Product
Table 119. Hengrui Pharmaceuticals Recent Developments/Updates
Table 120. Lunan Pharmaceutical Corporation Information
Table 121. Lunan Pharmaceutical Description and Business Overview
Table 122. Lunan Pharmaceutical Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Lunan Pharmaceutical Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Product
Table 124. Lunan Pharmaceutical Recent Developments/Updates
Table 125. Qilu Pharmaceutical Co., Ltd. Corporation Information
Table 126. Qilu Pharmaceutical Co., Ltd. Description and Business Overview
Table 127. Qilu Pharmaceutical Co., Ltd. Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Qilu Pharmaceutical Co., Ltd. Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Product
Table 129. Qilu Pharmaceutical Co., Ltd. Recent Developments/Updates
Table 130. CSPC Pharmaceutical Group Limited Corporation Information
Table 131. CSPC Pharmaceutical Group Limited Description and Business Overview
Table 132. CSPC Pharmaceutical Group Limited Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. CSPC Pharmaceutical Group Limited Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Product
Table 134. CSPC Pharmaceutical Group Limited Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Distributors List
Table 138. Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Customers List
Table 139. Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Trends
Table 140. Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Drivers
Table 141. Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Challenges
Table 142. Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor
Figure 2. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Share by Type in 2023 & 2030
Figure 4. Vials Product Picture
Figure 5. Prefilled Product Picture
Figure 6. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Share by Application in 2023 & 2030
Figure 8. Myelosuppressive Chemotherapy for Nonmyeloid Neoplasms
Figure 9. Chemotherapy for Hematological Malignancies Myelosuppression
Figure 10. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 11. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Size (2019-2030) & (US$ Million)
Figure 12. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales (2019-2030) & (K Units)
Figure 13. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Average Price (US$/Unit) & (2019-2030)
Figure 14. Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Report Years Considered
Figure 15. Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales Share by Manufacturers in 2023
Figure 16. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Share by Manufacturers in 2023
Figure 17. The Global 5 and 10 Largest Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Players: Market Share by Revenue in 2023
Figure 18. Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 19. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 20. North America Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales Market Share by Country (2019-2030)
Figure 21. North America Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Market Share by Country (2019-2030)
Figure 22. United States Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 23. Canada Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Europe Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales Market Share by Country (2019-2030)
Figure 25. Europe Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Market Share by Country (2019-2030)
Figure 26. Germany Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. France Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. U.K. Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Italy Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Russia Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Asia Pacific Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales Market Share by Region (2019-2030)
Figure 32. Asia Pacific Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Market Share by Region (2019-2030)
Figure 33. China Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Japan Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. South Korea Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. India Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Australia Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. China Taiwan Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Southeast Asia Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Latin America Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales Market Share by Country (2019-2030)
Figure 41. Latin America Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Market Share by Country (2019-2030)
Figure 42. Mexico Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Brazil Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Argentina Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Sales Market Share by Country (2019-2030)
Figure 46. Middle East & Africa Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Market Share by Country (2019-2030)
Figure 47. Turkey Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Saudi Arabia Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. UAE Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Global Sales Market Share of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor by Type (2019-2030)
Figure 51. Global Revenue Market Share of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor by Type (2019-2030)
Figure 52. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Price (US$/Unit) by Type (2019-2030)
Figure 53. Global Sales Market Share of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor by Application (2019-2030)
Figure 54. Global Revenue Market Share of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor by Application (2019-2030)
Figure 55. Global Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Price (US$/Unit) by Application (2019-2030)
Figure 56. Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Value Chain
Figure 57. Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Production Process
Figure 58. Channels of Distribution (Direct Vs Distribution)
Figure 59. Distributors Profiles
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
